Zalcitabine population pharmacokinetics: application of radioimmunoassay.

Antimicrobial Agents and Chemotherapy
J M AdamsG D Morse

Abstract

Zalcitabine population pharmacokinetics were evaluated in 44 human immunodeficiency virus-infected patients (39 males and 5 females) in our immunodeficiency clinic. Eighty-one blood samples were collected during routine clinic visits for the measurement of plasma zalcitabine concentrations by radioimmunoassay (1.84+/-1.24 samples/patient; range, 1 to 6 samples/patient). These data, along with dosing information, age (38.6+/-7.13 years), sex, weight (79.1+/-15.0 kg), and estimated creatinine clearance (89.1+/-21.5 ml/min), were entered into NONMEM to obtain population estimates for zalcitabine pharmacokinetic parameters. The standard curve of the radioimmunoassay ranged from 0.5 to 50.0 ng/ml. The observed concentrations of zalcitabine in plasma ranged from 2.01 to 8.57 ng/ml following the administration of doses of either 0.375 or 0.75 mg. A one-compartment model best fit the data. The addition of patient covariates did not improve the basic fit of the model to the data. Oral clearance was determined to be 14.8 liters/h (0.19 liter/h/kg; coefficient of variation [CV] = 23.8%), while the volume of distribution was estimated to be 87.6 liters (1.18 liters/kg; CV = 54.0%). We were also able to obtain individual estimates of oral c...Continue Reading

References

Oct 15, 1989·Biochemical Pharmacology·P G Plagemann, C Woffendin
Sep 14, 1989·The New England Journal of Medicine·R YarchoanS Broder
Nov 1, 1988·Biomedical & Environmental Mass Spectrometry·F R RubioE K Fukuda
Sep 1, 1988·Journal of Clinical Pharmacology·R W KleckerC E Myers
Apr 1, 1993·The Annals of Pharmacotherapy·M J SheltonG D Morse

❮ Previous
Next ❯

Citations

Aug 19, 2007·European Journal of Clinical Pharmacology·Xavière PanhardUNKNOWN Cophar 1 - ANRS 102 Study Group
May 25, 2005·Clinical Pharmacokinetics·Jeffrey S BarrettMarc Pfister

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.